Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07023315 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Name: A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma — clinical trial record (NCT07023315)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorAkeso

Started2025-08-14

View on ClinicalTrials.gov ↗

Amendment history

2026-02-09

Not Yet Recruiting→Recruiting Study Status, Arms and Interventions, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-07→confirmed 2025-08-14

InterventionsCadonilimab (Drug), SOX chemotherapy (Drug)→Cadonilimab (Drug), Placebo (Drug), SOX chemotherapy (Drug)

Study sitesdetails revised at 6 of 6 sites

2025-06-10

Original filing

Akeso

96 trials monitored

See 1 trial at risk

This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer.

Trial Details

NCT Number	NCT07023315
Lead Sponsor	Akeso
Conditions	Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Enrollment	760 participants
Start Date	2025-08-14
Primary Completion	2029-07 (estimated)
Study Completion	2031-07 (estimated)
Updated on ClinicalTrials.gov	2026-02-11